Simultaneous Detection of Ubiquinol-10, Ubiquinone-10, and Tocopherols in Human Plasma Microsamples and Macrosamples as a Marker of Oxidative Damage in Neonates and Infants

2000 ◽  
Vol 282 (2) ◽  
pp. 209-217 ◽  
Author(s):  
Thomas Menke ◽  
Petra Niklowitz ◽  
Stefan Adam ◽  
Michael Weber ◽  
Bernhard Schlüter ◽  
...  
Keyword(s):  
Oxidative Damage ◽  
Human Plasma ◽  
Simultaneous Detection ◽  
Neonates And Infants ◽  
Ubiquinone 10

A smart fluorescent probe for simultaneous detection of GSH and Cys in human plasma and cells

RSC Advances ◽  
2015 ◽  
Vol 5 (118) ◽  
pp. 97781-97787 ◽  
Author(s):  
Jian Pan ◽  
Yue Zhang ◽  
Junchao Xu ◽  
Jinbiao Liu ◽  
Lintao Zeng ◽  
...  
Keyword(s):  
Detection Limit ◽  
Human Plasma ◽  
Fluorescent Probe ◽  
Simultaneous Detection ◽  
Low Detection Limit ◽  
Emission Channel

A smart fluorescent probe was developed to simultaneously detect Cys and GSH in different emission channel with low detection limit.

scholarly journals Interaction of nitrogen dioxide with human plasma Antioxidant depletion and oxidative damage

FEBS Letters ◽  
1992 ◽  
Vol 313 (1) ◽  
pp. 62-66 ◽  
Author(s):  
Barry Halliwell ◽  
Miao-Lin Hu ◽  
Samuel Louie ◽  
Timothy R. Duvall ◽  
Brian K. Tarkington ◽  
...  
Keyword(s):  
Oxidative Damage ◽  
Nitrogen Dioxide ◽  
Human Plasma ◽  
Plasma Antioxidant

scholarly journals Implementation of Isavuconazole in a Fluorescence-Based High-Performance Liquid Chromatography Kit Allowing Simultaneous Detection of All Four Currently Licensed Mold-Active Triazoles

mSphere ◽  
2017 ◽  
Vol 2 (3) ◽  
Author(s):  
René Jørgensen ◽  
Siri Rytcher Andersen ◽  
Karen Marie Thyssen Astvad ◽  
Maiken Cavling Arendrup
Keyword(s):  
Invasive Aspergillosis ◽  
Human Plasma ◽  
Broad Spectrum ◽  
High Performance ◽  
Simultaneous Detection ◽  
Hplc Method ◽  
Therapeutic Window ◽  
Serum Samples ◽  
Accuracy And Precision ◽  
Highly Sensitive

ABSTRACT Isavuconazole is a new broad-spectrum triazole agent recently approved for the treatment of both invasive aspergillosis and mucormycosis. Currently, there is no consensus regarding the potential need for TDM of isavuconazole, and no therapeutic window has been defined. However, at the ECIL-6 meeting in 2015, it was advised that TDM is indicated in a number of different settings. In this study, we describe a rapid and validated isocratic HPLC method for fluorescence-based detection and quantification of isavuconazole in human plasma/serum samples. The method is simple and efficient with good accuracy and precision and importantly only requires a small volume of patient plasma/serum. Furthermore, this method is highly sensitive and selective and can be detected simultaneously with the three other triazoles, itraconazole, voriconazole, and posaconazole, without the need for expensive mass spectrometry equipment. Isavuconazole (ISZ) is a newly available broad-spectrum triazole agent recently approved for the treatment of both invasive aspergillosis and mucormycosis. The aim of this study was to develop a simple and reliable method for therapeutic drug monitoring (TDM) of ISZ in human plasma samples. The method involves using a kit from ChromSystems intended for TDM of itraconazole (ITZ), posaconazole (PSZ), and voriconazole (VRZ) in serum/plasma for sample preparation and high-performance liquid chromatography, using fluorescence detection with emission and excitation wavelengths set to 261 and 366 nm, respectively. The assay was linear over the ISZ concentration range of 0.2 to 20.0 mg/liter, using a 0.1-ml sample volume. The inter- and intraday coefficients of variation were all below 3.7%, whereas the accuracies ranged from 95.0 to 106.2% and the mean extraction recovery was 91.9%. In addition, the method worked well using four different Vacutainer types, with six different healthy volunteers and under a number of relevant storage conditions. Finally, the ISZ detection could be seamlessly implemented in the TDM kit for VRZ, PSZ, and ITZ, enabling simultaneous detection of all four triazoles. This method proved to be simple, accurate, precise, and well suited for routine analysis work. It has been implemented in our laboratory for the simultaneous quantitative analysis of ISZ, VRZ, PSZ, and ITZ for TDM and pharmacokinetic research. IMPORTANCE Isavuconazole is a new broad-spectrum triazole agent recently approved for the treatment of both invasive aspergillosis and mucormycosis. Currently, there is no consensus regarding the potential need for TDM of isavuconazole, and no therapeutic window has been defined. However, at the ECIL-6 meeting in 2015, it was advised that TDM is indicated in a number of different settings. In this study, we describe a rapid and validated isocratic HPLC method for fluorescence-based detection and quantification of isavuconazole in human plasma/serum samples. The method is simple and efficient with good accuracy and precision and importantly only requires a small volume of patient plasma/serum. Furthermore, this method is highly sensitive and selective and can be detected simultaneously with the three other triazoles, itraconazole, voriconazole, and posaconazole, without the need for expensive mass spectrometry equipment.

Sign in / Sign up

Export Citation Format

Share Document